A detailed history of Credit Suisse Ag transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 32,223 shares of MORF stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,223
Previous 23,960 34.49%
Holding current value
$1.1 Million
Previous $691,000 64.11%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$26.64 - $40.31 $220,126 - $333,081
8,263 Added 34.49%
32,223 $1.13 Million
Q4 2023

Feb 08, 2024

SELL
$19.95 - $31.0 $26,932 - $41,850
-1,350 Reduced 5.33%
23,960 $691,000
Q3 2023

Nov 13, 2023

SELL
$21.33 - $59.42 $140,372 - $391,043
-6,581 Reduced 20.64%
25,310 $579,000
Q2 2023

Aug 11, 2023

BUY
$34.33 - $62.11 $418,860 - $757,804
12,201 Added 61.97%
31,891 $1.83 Million
Q1 2023

May 10, 2023

BUY
$26.01 - $48.69 $34,073 - $63,783
1,310 Added 7.13%
19,690 $741,000
Q4 2022

Feb 13, 2023

BUY
$24.14 - $30.37 $118,623 - $149,238
4,914 Added 36.49%
18,380 $491,000
Q3 2022

Nov 10, 2022

BUY
$22.23 - $33.37 $15,005 - $22,524
675 Added 5.28%
13,466 $381,000
Q2 2022

Aug 12, 2022

SELL
$19.74 - $43.01 $5,408 - $11,784
-274 Reduced 2.1%
12,791 $277,000
Q1 2022

May 16, 2022

BUY
$36.25 - $52.02 $35,488 - $50,927
979 Added 8.1%
13,065 $524,000
Q4 2021

Feb 14, 2022

BUY
$43.27 - $65.72 $5,927 - $9,003
137 Added 1.15%
12,086 $572,000
Q3 2021

Nov 12, 2021

BUY
$53.61 - $67.5 $52,001 - $65,475
970 Added 8.84%
11,949 $677,000
Q2 2021

Aug 16, 2021

BUY
$45.13 - $64.99 $24,099 - $34,704
534 Added 5.11%
10,979 $630,000
Q1 2021

May 14, 2021

SELL
$29.77 - $84.85 $77,134 - $219,846
-2,591 Reduced 19.88%
10,445 $662,000
Q4 2020

Feb 12, 2021

BUY
$25.66 - $34.55 $334,503 - $450,393
13,036 New
13,036 $437,000

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $1.31B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.